Roche Holding Announces Positive Data Regarding Its New Heart Attack Diagnosis Test, Stock Up

(RTTNews) - Roche Holding AG (RHHBY.PK), Tuesday announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Elecsys Troponin T test for diagnosing heart attacks.

The results showed that the test was able to detect even the slightest elevations in troponin levels, a critical biomarker for heart attack, enabling patients to receive life-saving care at the earliest.

It also identified whether patients had acute myocardial infarction or not with huge precision, helping clinicians to provide faster and reliable diagnosis in emergencies.

Currently, Roche's stock is moving up 3.33 percent, to $40.91 on the OTC Markets.